Experiences with recombinant factor VIIa for the prevention of bleeding in patients with chronic liver disease undergoing percutaneous liver biopsies and endoscopic retrograde cholangiopancreatography (ERCP).
Kositchaiwat
C
C
Chuansumrit
A
A
D000328:Adult; D000368:Aged; D001707:Biopsy, Needle / Q000009:adverse effects*; D002760:Cholangiopancreatography, Endoscopic Retrograde / Q000009:adverse effects*; D015942:Factor VIIa / Q000235:genetics / Q000627:therapeutic use*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D006470:Hemorrhage / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D008099:Liver / Q000473:pathology; D008107:Liver Diseases / Q000150:complications*; D008297:Male; D008875:Middle Aged; D010314:Partial Thromboplastin Time; D011517:Prothrombin Time; D011994:Recombinant Proteins / Q000627:therapeutic use; D016896:Treatment Outcome
D005338:Fibrin Fibrinogen Degradation Products; D011994:Recombinant Proteins; C036309:fibrin fragment D; D015942:Factor VIIa